

### Patent Docket P1998R1

# THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Alex Abbas et al.

Serial No.: 10/533,401

Filed: April 28, 2005

For:

Compositions and Methods for the

Treatment of Rheumatoid Arthritis

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

Confirmation No: Not Known

CUSTOMER NO: 09157

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 25, 2005

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

#### [x] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§ 1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

#### 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of Serial No.: 10/533,401 Filing Date: April 28, 2005

4 - -

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

### [] 37 CFR §1.97(d)

 after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (\*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. 60/425,931, filed November 12, 2002 and benefit from the prior application is claimed in this application under 35 U.S.C §120. However, copies of any cited

Serial No.: 10/533,401 Filing Date: April 28, 2005

Page 3

document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

- [x] not given
- [] given for each listed item
- [] given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: August 25, 2005

David A. Carpenter, Ph.D.

Reg. No. 45,945

Telephone No. (650) 225-3733

1 DNA Way So. San Francisco, CA 94080-4990 Facsimile No. (650) 952-9881

	OIFE TO	
	AUG 3 0 2005	
FORM PTO-144	TRADEMENTS	

Sheet 1	of	1	

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.	Serial No.
P1998R1	10/533,401
Applicant	

Applicant

Abbas Alex et al.

Filing Date Group

28 Apr 2005 Not Yet Assigned

# LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

				FOREIGN PATENT DOCUMENT	S			
xaminer nitials		Document Number	Date	Country	Class	Subclass	Transla Yes	ation No
	1	WO 01/75166 A2	11.10.01	PCT				
			OTHER DISCL	OSURES (Including Author, Title, Date,	Pertinent Pages, e	tc.)		
	2	• · · · · · · · · · · · · · · · · · · ·	•	ansplantation and Graft Rejection en Press Ltd., Chapter 33, pps.		Immunology,	William	E.

Issekutz et al., "Treatment of Established Adjuvant Arthritis in Rats with Monoclonal Antibody to CD18
and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-Lymphocyte Migration to the
Joints and Improves Clinical Disease" Immunology 88:569-576 (1996)

Coligan et al, eds., "Proliferative Assays for T Cell Function" <u>Current Protocols in Immunology</u>, John Wiley & Sons, Inc., Chapter 3.12, Vol. 1 (1991)

Examiner Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.